WeissR, GargSK, BodeBW, BaileyTS, AhmannAJ, SchultzKA, WelshJB, ShinJJ; ASPIRE In-Home Study Group: Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE In-Home study. Diabetes Technol Ther, 2015; 17:542–547.
2.
RohlfingCL, WiedmeyerHM, LittleRR, EnglandJD, TennillA, GoldsteinDE: Defining the relationship between plasma glucose and HbA1c. Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care, 2002; 25:275–278.
3.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in the diabetes control in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
4.
The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes, 1997; 46:271–286.
5.
AshwellSG, AmielSA, BilousRW, DashoraU, HellerSR, HepburnDA, ShutlerSD, StephensJW, HomePD: Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med, 2006; 23:285–292.
6.
HomePD: The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab, 2012; 14:780–788.
7.
YagasakiH, KobayashiK, SaitouT, NagamineK, MitsuiY, MochizukiM, KobayashiK, ChoH, OhyamaK, AmemiyaS, NakazawaS: Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: differences in the dawn phenomenon between insulin regimens. Exp Clin Endocrinol Diabetes, 2010; 118:195–199.
8.
VagueP, SelamJL, SkeieS, De LeeuwI, ElteJW, HaarhH, KristensenA, DraegerE: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care, 2003; 26:590–596.
9.
DanneT, BattelinoT, Jarosz-ChobotP, KordonouriO, PankowskaE, LudvigssonJ, SchoberE, KaprioE, SaukkonenT, NicolinoM, Tubiana-RufiN, KlinkertC, HaberlandH, VazeouA, MadacsyL, ZangenD, CherubiniV, RabboneI, ToniS, de BeaufortC, Bakker-van WaardeW, van den BergN, VolkovI, BarrioR, HanasR, ZumstegU, KuhlmannB, AebiC, SchumacherU, GschwendS, HindmarshP, TorresM, ShehadehN, PhillipM; PedPump Study Group: Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries. Diabetologia, 2008; 51:1594–1601.
10.
MelkiV, RenardE, Lassmann-VagueV, BoivinS, GuerciB, Hanaire-BroutinH, BringerJ, BelicarP, JeandidierN, MeyerL, BlinP, Augendre-FerranteB, TauberJP: Improvement of HbA1c and blood glucose stability in IDDM patients treated with Lispro insulin analog in external pumps. Diabetes Care, 1998; 21:977–982.
11.
RivelineJP, SchaepelynckP, ChaillousL, RenardE, Sola-GazagnesA, PenfornisA, Tubiana-RufiN, SulmontV, CatargiB, LukasC, RadermeckerRP, ThivoletC, MoreauF, BenhamouPY, GuerciB, LeguerrierAM, MillotL, SachonC, CharpentierG, HanaireH; EVADIAC Sensor Study Group: Assessment of patient-led or physician-driven continuous glucose monitoring (CGM) in poorly controlled type 1 diabetic patients using basal-bolus insulin regimens: A one-year multicenter study. Diabetes Care, 2012; 35:965–971.
12.
Hanaire-BroutinH, BroussolleC, JeandidierN, RenardE, GuerciB, HaardtMJ, Lassmann-VagueV; Evadiac Study Group: Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in insulin dependent diabetes: multicenter study. Diabetes Care, 1995; 18:388–392.
13.
NimriR, MullerI, AtlasE, MillerS, FogelA, BratinaN, KordonouriO, BattelinoT, DanneT, PhillipM: MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care, 2014; 37:3025–3032.
14.
Del FaveroS, PlaceJ, KropffJ, MessoriM, Keith-HynesP, VisentinR, MonaroM, GalassoS, BoscariF, ToffaninC, Di PalmaF, LanzolaG, ScarpelliniS, FarretA, KovatchevB, AvogaroA, BruttomessoD, MagniL, DeVriesJH, CobelliC, RenardE; the AP@home Consortium: Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. Diabetes Obes Metab, 2015; 17:468–476.
15.
DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment for Normal Eating (DAFNE) randomised controlled trial. BMJ, 2002; 325:746.
16.
JinSM, KimTH, BaeJC, HurKY, LeeMS, LeeMK, KimJH: Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. Diabetes Res Clin Pract, 2014; 104:266–272.
17.
BuckinghamB, ChengP, BeckRW, KollmanC, RuedyKJ, WeinzimerSA, SloverR, BremerAA, FuquaJ, TamborlaneW; Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups: CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia, 2015; 58:1167–1174.
18.
PickupJC, KiddJ, BurmistonS, YemaneN: Determinants of glycemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev, 2006; 22:232–237.
